What are the pharmacokinetics of fusion inhibitors (FIs) in antiretroviral therapy of HIV infection?

Updated: Apr 18, 2019
  • Author: R Chris Rathbun, PharmD, BCPS (AQ-ID), AAHIVP; Chief Editor: John Bartlett, MD  more...
  • Print
Answer

Answer

Enfuvirtide therapy requires twice-daily subcutaneous injection. It has not been shown to influence the metabolism of concomitant medications through the cytochrome P450 system.

Dose adjustments are not required in patients with renal insufficiency or mild-to-moderate hepatic insufficiency. Limited dosing data exist for patients with advanced liver disease; therefore, enfuvirtide should be used with caution in patients with hepatic decompensation. [8, 96]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!